FDA approved AstraZeneca’s Brilinta to reduce the risk of stroke

The FINANCIAL — AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of stroke, a leading cause of disability and death worldwide, in patients with acute ischemic stroke (National Institutes of Health Stroke Scale score ≤5) or high-risk transient ischaemic attack…

3 mins read

EU approved AstraZeneca’s Forxiga for heart failure

The FINANCIAL — AstraZeneca’s Forxiga (dapagliflozin) has been approved in the European Union (EU) for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF) in adults with and without type-2 diabetes (T2D). Heart failure (HF) is a life-threatening chronic disease that…

4 mins read

CHMP recommended approving Forxiga for heart failure treatment

The FINANCIAL — AstraZeneca’s Forxiga (dapagliflozin) has been recommended for an indication extension of its marketing authorisation in the European Union (EU) for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF) in adults with and without type-2 diabetes (T2D). Heart…

6 mins read

AstraZeneca’s Trixeo Aerosphere recommended for approval in the EU

The FINANCIAL — AstraZeneca’s Trixeo Aerosphere (formoterol fumarate/glycopyrronium bromide/budesonide) has been recommended for marketing authorisation in the European Union (EU) for maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of…

3 mins read

Oxford COVID-19 vaccine trial pauses after volunteer falls ill

The FINANCIAL — The outcome of vaccine trials is being closely watched around the world. Pharmaceutical company AstaZeneca said Tuesday that it had paused global trials of its coronavirus vaccine in America as it is investigating one of the volunteers in United Kingdom…

6 mins read